Kaplan Fox Encourages Microvast Holdings, Inc. (NASDAQ: MVST) Investors to Contact the Firm Before the Deadline on September 21, 2026

A securities class action has been filed against Microvast over alleged misstatements regarding its Huzhou Phase 3.2 capacity expansion and expected margin improvement. The complaint cites Q4 2025 gross margin collapsing to approximately 1% from approximately 36% a year earlier, alongside quarterly revenue of $96.5 million, down 15% year over year. Allegations also include overstated production activity and commercial opportunities, creating material litigation and credibility risks for MVST.

Analysis

The relevant investable issue is not the lawsuit itself, which is typically non-informational, but whether the underlying operating reset leaves MVST dependent on external capital before its manufacturing assets generate sustainable cash returns. A near-breakeven gross-margin quarter combined with inventory write-downs raises the probability of further working-capital absorption, covenant pressure, or dilutive financing; in subscale battery manufacturers, that risk can dominate any recovery in reported revenue over the next 6-12 months.

The credibility discount should persist until management demonstrates three independently measurable improvements: normalized gross margin excluding inventory actions, conversion of backlog into customer shipments, and utilization at the expanded facility. If commercial-vehicle customer launches remain delayed, fixed-cost absorption can keep margins depressed even if revenue stabilizes, making a revenue-only rebound a potential value trap. The next earnings release and cash-flow disclosure are the principal 1-3 month catalysts, rather than the September litigation deadline.

There is limited clean read-through to larger battery or energy-storage names: the issue appears company-specific execution and inventory quality rather than an industry demand signal. A contrarian upside case exists if impaired components are isolated and new capacity is already operational, but that requires evidence in inventory turns, operating cash flow, and order conversion—not management commentary. The short thesis is falsified by two consecutive quarters of positive operating cash flow, gross margin sustainably above 15%, and no incremental equity or convertible issuance.

Key Decisions for Investors

• Maintain no core long exposure to MVST pending the next quarterly filing; treat any litigation-deadline volatility as technical rather than fundamental.
• For a tactical bearish mandate, consider a small MVST short only after confirming borrow availability and cost, with a 1-3 month horizon through the next earnings release. Size conservatively given low-float/short-squeeze risk; cover if gross margin exceeds 15% without further inventory charges or if operating cash flow turns positive.
• If listed options have adequate open interest, prefer a defined-risk MVST put spread expiring after the next earnings report rather than an outright short; do not execute if implied volatility already prices a move greater than the expected downside or bid-ask spreads are excessive.
• Monitor cash, restricted cash, receivables, inventory days, and any shelf registration, ATM, convertible, or debt amendment. A financing announcement would validate balance-sheet risk; absence of financing alongside improving cash conversion would weaken the bear case.
• Do not use BAC as a sympathy hedge or trade expression; it has no identifiable economic linkage to this company-specific litigation.